Shockwave therapy for erectile dysfunction has moved from academic urology departments into strip-mall clinics in under a decade, usually advertised as a drug-free way to "restore" erections. The underlying premise is genuinely novel: rather than amplifying a signal on demand the way an oral medication does, low-intensity shockwave therapy is proposed to remodel penile vascular tissue itself. That is a strong claim, and it deserves a careful look at what the randomized, sham-controlled trials actually measured, in whom, and for how long.
What Low-Intensity Shockwave Therapy Actually Is
Low-intensity shockwave therapy (LiST, also written Li-ESWT or LiSWT) delivers acoustic pressure waves to the penile shaft, crura, and base through a handheld probe. The energy is roughly a hundredth of the intensity used to fragment kidney stones — energy flux densities in published protocols cluster around 0.09 to 0.16 mJ/mm², with 1,500 to 5,000 impulses per session and typically four to twelve sessions delivered over three to six weeks [1,2].
No anesthesia is used, sessions run fifteen to twenty minutes, and reported adverse events across the randomized literature are minimal — mild transient discomfort at most. That safety profile is one reason the therapy spread so quickly, and it is also why the more interesting question is efficacy rather than risk.
Protocols, however, are not standardized. Device type, energy density, impulse count, session frequency, and treatment sites all vary between published trials, which makes pooled analysis genuinely difficult and makes any given clinic's protocol only loosely related to the protocols that generated the published results.
The Mechanism: Angiogenesis, Not Vasodilation
The mechanistic rationale separates shockwave therapy from every oral option. Phosphodiesterase type 5 inhibitors work downstream of nitric oxide, preventing the breakdown of cyclic GMP so that smooth muscle relaxes when sexual stimulation occurs. They amplify an existing signal; they do not change the tissue.
Shockwave therapy is proposed to act through mechanotransduction: controlled microtrauma triggers release of angiogenic growth factors, recruitment of progenitor cells, and formation of new microvasculature within the corpora cavernosa. Animal work supports the tissue-level premise. In naturally aged rats, low-intensity shockwave therapy was associated with measurable changes in erectile tissue architecture, consistent with a regenerative rather than purely functional effect [3].
Human hemodynamic data are more mixed but not absent. A sham-controlled trial using triplex ultrasonography reported improvement in penile hemodynamic parameters after treatment in men with vasculogenic erectile dysfunction [4]. Other randomized work has failed to show significant changes in peak systolic velocity, end-diastolic velocity, or resistive index, which is a meaningful tension in the literature: symptom scores often improve when objective Doppler parameters do not.
What the Randomized Evidence Shows
The strongest single trial is a double-blind, randomized, sham-controlled study of seventy men with moderate erectile dysfunction, randomized to twelve sessions of LiST or sham therapy twice weekly. At three months, the minimal clinically important difference in the International Index of Erectile Function–Erectile Function domain (IIEF-EF) was reached by 79% of treated men versus none in the sham arm, with a baseline-adjusted between-group difference of 4.4 points [1]. Blinding was maintained, the effect size exceeded the threshold clinicians consider meaningful, and no significant adverse events were recorded.
Pooled analyses are directionally consistent but more modest. An early systematic review and meta-analysis of randomized controlled trials found statistically significant IIEF improvement with shockwave therapy over sham [2]. A 2025 updated meta-analysis of twelve randomized sham-controlled trials in 882 men with vasculogenic erectile dysfunction reported a mean IIEF-EF difference of 2.28 points favoring treatment, along with higher rates of an Erection Hardness Score of 3 or greater [5].
A 2026 systematic review of twelve randomized trials tempered this further, finding significant improvement in IIEF-5 and IIEF-EF scores but no significant differences in Erection Hardness Score, Sexual Encounter Profile responses, or penile Doppler parameters, and concluding that current evidence does not support routine inclusion of the therapy in standard treatment algorithms [6].
The honest summary: the direction of effect is consistent across randomized evidence, the magnitude ranges from modest to clinically meaningful depending on the population studied, and the objective vascular endpoints lag behind the questionnaire scores.
Who Responds and Who Does Not
Response is not uniform, and the severity-stratified work is the most clinically useful part of this literature. Three parallel double-blind randomized trials examined protocols matched to baseline severity [2]:
- Mild erectile dysfunction (IIEF-EF 17–25): six sessions combined with daily 5 mg tadalafil produced significantly better erectile function at three months than shockwave therapy alone.
- Moderate erectile dysfunction (IIEF-EF 11–16): twelve sessions as monotherapy significantly outperformed sham.
- Severe erectile dysfunction (IIEF-EF 1–10): twelve sessions combined with daily 5 mg tadalafil outperformed sham plus tadalafil in partial responders to oral therapy.
Two patterns matter here. First, benefit was documented specifically in vasculogenic erectile dysfunction — men whose difficulty is driven by impaired arterial inflow rather than by neurologic injury, hormonal deficiency, or psychogenic factors. Second, in mild and severe disease, the best outcomes came from shockwave therapy plus a daily phosphodiesterase type 5 inhibitor, not from shockwave therapy instead of one. Clinical series also suggest that men with long-standing diabetes tend to respond less well, which is consistent with the degree of underlying microvascular damage.
Limitations, Cost, and Where Guidelines Stand
Three limitations should shape expectations. Durability is the first: most trials report outcomes at one to three months, some at six to twelve, and evidence beyond two years is thin. Whether repeat courses are needed, and how often, remains unresolved. Protocol heterogeneity is the second: a clinic advertising "shockwave therapy" may use a radial pressure-wave device, which is not the same technology tested in most focused-shockwave trials. Cost is the third — courses are typically self-funded and often run into the thousands of dollars, since coverage is uncommon.
Guideline bodies reflect this uncertainty. European guidance positions shockwave therapy as an option in mild vasculogenic erectile dysfunction, for men who prefer an alternative to oral therapy, and for poor responders to phosphodiesterase type 5 inhibitors — while noting the evidence base is limited. North American guidance is more conservative, treating the therapy as investigational outside research settings. Neither body recommends it as first-line therapy, and both continue to place oral phosphodiesterase type 5 inhibitors there, backed by decades of trial data.
Conclusion
Shockwave therapy for erectile dysfunction is neither the breakthrough the marketing suggests nor the placebo the skeptics assume. Randomized sham-controlled data support a real, modest benefit in carefully selected men with vasculogenic disease, with the strongest results in moderate severity and in combination with a daily phosphodiesterase type 5 inhibitor. It is not a cure, it is not first-line, and it is not appropriate for erectile dysfunction driven by hormonal, neurologic, or psychological causes.
For most men, the sequence that the evidence supports is unchanged: evaluate the vascular and metabolic drivers first, since erectile dysfunction is frequently the earliest visible sign of systemic endothelial disease, then establish an effective medical regimen, and consider procedural options as an adjunct rather than a replacement. Our other clinical reviews on vascular and metabolic contributors are collected on the OnyxMD blog.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans — including VAST, a sublingual triple-mechanism formulation developed for men who respond incompletely to standard oral therapy — starting with a free online assessment at questionnaire.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
- Kalyvianakis D, Mykoniatis I, Pyrgidis N, Kapoteli P, Zilotis F, Fournaraki A, Hatzichristou D. The Effect of Low-Intensity Shock Wave Therapy on Moderate Erectile Dysfunction: A Double-Blind, Randomized, Sham-Controlled Clinical Trial. Journal of Urology. 2022;208(2):388–395. doi:10.1097/JU.0000000000002684
- Pyrgidis N, Kalyvianakis D, Mykoniatis I, Hatzichristou D. The recommended treatment protocol for low-intensity shockwave therapy based on the severity of erectile dysfunction. International Journal of Impotence Research. 2025;37(7):566–568. doi:10.1038/s41443-024-00959-7
- Sokolakis I, Dimitriadis F, Psalla D, Karakiulakis G, Kalyvianakis D, Hatzichristou D. Effects of low-intensity shock wave therapy (LiST) on the erectile tissue of naturally aged rats. International Journal of Impotence Research. 2019;31(3):162–169. doi:10.1038/s41443-018-0064-0
- Kalyvianakis D, Hatzichristou D. Low-Intensity Shockwave Therapy Improves Hemodynamic Parameters in Patients With Vasculogenic Erectile Dysfunction: A Triplex Ultrasonography-Based Sham-Controlled Trial. Journal of Sexual Medicine. 2017;14(7):891–897. doi:10.1016/j.jsxm.2017.05.012
- Sokolakis I, Hatzichristodoulou G. Clinical studies on low intensity extracorporeal shockwave therapy for erectile dysfunction: a systematic review and meta-analysis of randomised controlled trials. International Journal of Impotence Research. 2019;31(3):177–194. doi:10.1038/s41443-019-0117-z
- Efficacy of low-intensity extracorporeal shock wave therapy for erectile dysfunction: updated meta-analysis of randomized trials. Future Science OA. 2025;11(1):2511438. doi:10.1080/20565623.2025.2511438
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.